Climb Bio presents preclinical data on CLYM116 at ASN Kideny Week

Climb Bio (CLYM) announced the upcoming presentation of CLYM116 preclinical data and published budoprutug pMN Phase 1b long-term outcome data at the 2025 American Society of Nephrology Kidney Week, which will be held in Houston, TX November 6-9, 2025. Climb Bio will present additional preclinical data characterizing CLYM116, a novel ‘sweeper’ anti-APRIL monoclonal antibody, which is being developed to treat IgAN. In preclinical models, CLYM116 promoted APRIL degradation and demonstrated enhanced antibody recycling, leading to deep and durable reduction of IgA. On September 29, 2025, Climb Bio held an R&D Spotlight Webcast focused on CLYM116 to review initial preclinical data and the development opportunity in IgAN. The company also published an abstract providing new clinical data from its budoprutug program, a novel anti-CD19 monoclonal antibody in development for B-cell mediated diseases. Long-term follow-up clinical data from the previously conducted Phase 1b trial in pMN demonstrated long-term control of proteinuria for up to three years after initial dosing in four patients who received up to four doses of budoprutug. Additionally, in three of these patients, no further immunosuppressive treatment was required. In the study, no clinically significant treatment-related adverse events were observed. These results, along with other available data, support further investigation of budoprutug as a potential disease-modifying therapy for pMN and other B-cell-mediated diseases.